VUNO Collaborates with European Partners to Enhance DeepCARS® Deployment in Europe

VUNO's Strategic Leap into Europe with DeepCARS®

In an effort to bolster its footprint in the European medical landscape, VUNO Inc., a pioneering medical AI firm based in South Korea, has announced a significant partnership. On October 27th, VUNO signed a Memorandum of Understanding (MOU) with Contextflow, an AI imaging specialist from Austria, and Mesalvo, a leading hospital information systems provider in Germany. This strategic alliance aims to facilitate the introduction of VUNO's breakthrough cardiac arrest prediction tool, VUNO Med®–DeepCARS®, across European hospitals.

The historic agreement was inked during the 38th Annual Congress of the European Society of Intensive Care Medicine (ESICM LIVES 2025), held in Munich from October 25 to 29. Through this collaboration, the three companies plan to focus on technical integration, real-world validation, and strategic reimbursement frameworks to facilitate DeepCARS' widespread adoption throughout Europe.

Advancing Technology and Collaboration

Under the terms of the MOU, Contextflow brings its intricate knowledge of regulatory and reimbursement processes related to imaging AI in Europe. This expertise will be pivotal in ensuring that DeepCARS meets all regulatory standards and gains the necessary market access as it rolls out across various healthcare systems.

On the other hand, Mesalvo's role will be crucial as they work to embed DeepCARS into their electronic health record (EHR) systems, which are widely used in over 900 hospitals throughout Europe. This merge of technology ensures that DeepCARS can smoothly process patient data and deliver timely warnings regarding cardiac arrest risks.

The potential impact of this integration is profound; with access to more than 900 hospitals, the partnership sets a solid foundation for transforming patient care across the continent. VUNO's ambitious plans coincide with their demonstration of DeepCARS at ESICM 2025, under the banner "Predict Early, Prevent More." This slogan encapsulates the proactive approach that VUNO is pioneering, which seeks to enhance patient outcomes through predictive analytics.

A New Standard in Patient Care

Dr. Ye Ha Lee, the Founder and CEO of VUNO, articulated the significance of this partnership, stating, "This strategic MOU with Contextflow and Mesalvo marks a significant step toward DeepCARS' expansion into Europe. By working closely with trusted local partners, we aim to set a new global standard in AI-based patient care that European hospitals and medical professionals can rely on."

This collaboration aims to enhance the existing capabilities of healthcare providers, providing them with tools that can potentially save lives. DeepCARS, which has already become an integral part of patient monitoring in South Korea, is designed to predict the likelihood of a patient experiencing a cardiac arrest within a 24-hour window. By analyzing vital parameters like blood pressure, heart rate, respiratory rate, and body temperature, DeepCARS delivers predictive alerts that empower healthcare teams to intervene promptly.

Transforming the Landscape of Healthcare

As of September 2025, DeepCARS is already in use across more than 50,000 hospital beds in South Korea, including around 20 tertiary care hospitals. The device has received non-stop recognition and accolades for its innovative approach to healthcare. In 2023, it even received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and is currently undergoing the approval process in the United States, highlighting its international potential.

In closing, VUNO's entry into the European market marks a pivotal moment in the integration of AI technologies into healthcare. By partnering with local leaders like Contextflow and Mesalvo, VUNO not only extends its reach but also enhances the quality of care that can be provided to patients. This innovative approach represents a significant leap towards achieving better health outcomes worldwide, showcasing the promising future of AI within the medical field.